The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Temporal and spatial topography of cell proliferation in cancer.
 
Sheheryar Kairas Kabraji
No Relationships to Disclose
 
Giorgio Gaglia
No Relationships to Disclose
 
Danae Argyropoulou
No Relationships to Disclose
 
Yang Dai
No Relationships to Disclose
 
Shu Wang
No Relationships to Disclose
 
Johann Bergholz
Consulting or Advisory Role - Geode Therapeutics
Patents, Royalties, Other Intellectual Property - Co-inventor of DFCI 2180.001 (DFS-166.25)
 
Shannon Coy
No Relationships to Disclose
 
Jia-Ren Lin
No Relationships to Disclose
 
Rinath Jeselsohn
No Relationships to Disclose
 
Otto Metzger
Honoraria - Grupo Oncoclinicas; Roche
Research Funding - Abbvie (Inst); Cascadian Therapeutics (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst); Susan G. Komen for the Cure (Inst)
Travel, Accommodations, Expenses - Grupo Oncoclinicas
 
Eric P. Winer
Honoraria - Genentech/Roche; Genomic Health
Consulting or Advisory Role - Athenex; Carrick Therapeutics; G1 Therapeutics; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Jounce Therapeutics; Leap Therapeutics; Lilly; Seagen; Syros Pharmaceuticals; Zymeworks
Research Funding - Genentech (Inst)
Other Relationship - InfiniteMD
 
Deborah Dillon
Consulting or Advisory Role - Novartis; Oncology Analytics
Travel, Accommodations, Expenses - Novartis
 
Jean Zhao
Leadership - Crimson BioPharm; Geode Therapeutics
Stock and Other Ownership Interests - Crimson BioPharm; Geode Therapeutics
Research Funding - Lilly; Puma Biotechnology
Patents, Royalties, Other Intellectual Property - I have several IPs at DFCI
 
Peter Sorger
Consulting or Advisory Role - NanoString Technologies; Rarecells
Other Relationship - Glencoe Software
 
Sandro Santagata
Consulting or Advisory Role - BioReference Laboratories (I)
Patents, Royalties, Other Intellectual Property - "Targeted Manipulation of the Proteasome Subunit Expression Levels as a Method for Curing Cancer” Application pending; “Combination Treatments of Hsp90 Inhibitors for Enhancing Tumor Immunogenicity and Methods of Use Thereof” Application pending; US20150241436A1 Hsf1 and hsf1 cancer signature set genes and uses relating thereto Abstract In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products. In some aspects, the invention provides methods of tumor dia; US20170037480A1 Hsf1 in tumor stroma Abstract In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products in tumor stroma. In some aspects, the invention provides methods of tumor prognosis, treatment-specific pre; US20170037480A1 Hsf1 in tumor stroma Abstract In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products in tumor stroma. In some aspects, the invention provides methods of tumor prognosis, treatment-specific pre; US20180306796A1 Methods and compositions relating to proteasome inhibitor resistance Abstract In some aspects, the disclosure provides methods of modulating the level of proteasome inhibitor resistance of a cell, the methods comprising manipulating th; US9696313B2 HSF1 as a marker in tumor prognosis and treatment Abstract In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products. In some aspects, the invention provides methods of tumor diagnosis, prognosis, trea